The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 349:2572-2573 December 25, 2003 Number 26
NextNext

Pure Red-Cell Aplasia Secondary to Antierythropoietin Antibodies

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-PubMed Citation
To the Editor: The use of recombinant human erythropoietin in patients with kidney disease is widespread and has been associated with few complications. Recent reports have suggested that the incidence of pure red-cell aplasia is increasing among European patients, who are often treated with subcutaneous epoetin alfa (Eprex).1,2 Neutralizing antierythropoietin antibodies were detected in these patients. We describe a case of pure red-cell aplasia in an American patient who was receiving epoetin alfa (Procrit, Ortho Biotech). Antierythropoietin antibodies were found to be neutralizing in vivo and in a murine erythroid cell line.

A 66-year-old woman with polycystic disease had chronic . . . [Full Text of this Article]


This article has been cited by other articles:


HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.